Fenochio-González F, Pichardo-Cuevas M, Linares-Pérez ML, Contreras-Carreto NA

Language: Spanish
References: 15
Page: 60-63
PDF size: 74.36 Kb.

ABSTRACT

Introduction. Hormonal and metabolic changes implicit in menopause, are set towards body weight increase and android redistribution of fat, produce peripheral insulin resistance, blood pressure elevation an dyslipidemia; all of them known today as main components of metabolic syndrome (MS); a strong predictor of cardiovascular diseases and eventually early death. Estrogenic therapy has shown beneficial effects over some of the components of MS previously mentioned, potentially contributing to reduce the mobility and mortality secondary to ischemic heart disease. Objective. To determine the prevalence of MS in postmenopausal women in order to compare different hormonal therapies available. Material and methods. Design has a transversal, retrospective, observational, descriptive, conducted since January 1st to April 30th 2011 in Women’s Hospital, Ministry of Health. Results. The incidence of MS was 72.2% (n = 182). There was no statistical significance in the reduction of MS in the oral therapy (p = 0.08 estrogen, estrogen + progestin p = 0.12) transdermal treatment showed a lower incidence of MS (p ≤ 0.05 for estrogen and estrogen-progestin). Conclusions. The prevalence of metabolic syndrome in this patient group is high. This prevalence appears to be reduced with the use of hormone replacement therapy (Especially in transdermal administration), but cannot be conclusive in this regard.

REFERENCES

1. Fernández Alonso AM. Terapia hormonal sustitutiva: diez años después. Tesis Doctoral. Departamento de Ginecología y Obstetricia. España: Universidad de Granada. Abril 2008.

2. Lobo RA. Síndrome metabólico después de la menopausia y el papel de las hormonas. Revista del climaterio 2009; 13: 1-10.

3. Alonso García A, Llaneza Coto P, González González C. Síndrome metabólico, obesidad y terapia hormonal de sustitución. Revista Española de Obesidad 2008; 6: 340-50.

4. Sócrates Aedo M, Arnaldo Porcile J, Domingo Laiz R, Fernando Urzúa V. Implicancias de diferentes modalidades de THR oral en los componentes del síndrome metabólico en las mujeres en climaterio del servicio de salud metropolitano oriente (Santiago de Chile). Rev Obstet Ginecol 2006; 1: 23-9.

5. Kirsten J. Menopausia y transición menopáusica. Clínicas Médicas de Norteamérica 2008; 92: 1253-71.

6. Carranza Madrigal J, López Correa S. El síndrome metabólico en México. Med Int Mex 2008; 24: 251-61.

7. Hernández Galván R, Jiménez Huerta J, Sánchez Contreras J. Incidencia de síndrome metabólico en la etapa de climaterio en el servicio de ginecología del Hospital Juárez de México. Rev Hosp Jua Mex 2008; 75: 241-6.

8. Ghosh A. Comparison of risk variables associated with the metabolic syndrome in pre- and postmenopausal Bengalee women. Cardiovasc J Afr 2008; 19: 183-7.

9. Razzouk L, Muntner P. Ethnic, gender, and age-related differences in patients with the metabolic syndrome. Curr Hypertens Rep 2009; 11: 127-32.

10. Carranza Lira S, Guerrero Millis L, Castro A. Frecuencia del síndrome metabólico en mujeres postmenopáusicas mexicanas y su relación con la terapia hormonal. Ginecol Obstet Mex 2009; 77: 367-71.

11. Whitcroft S, Herriot A. Insulin resistance and management of the menopause: a clinical hypothesis in practice. Menopause Int 2011; 17: 24-8.

12. Morato Hernández L, Malacara Hernández JM. Condiciones metabólicas y hormonales en la menopausia. Rev Endocrinol Nutr 2006; 14: 149-55.

13. Albuquerque de Figueiredo Net J, Durans Figuerêdo E, Bonifácio Barbosa J, Flores Barbosa F, Cardoso Costa GR, Da Silva Nina VJ, Vilela de Abreu Haickel R. Síndrome metabólico y menopausia: estudio transversal en ambulatorio de ginecología. Arq Bras Cardiol 2010; 95: 339-45.

14. Ouyang P, Michos ED, Karas RH. Hormone replacement therapy and the cardiovascular system: lessons learned and unanswered questions. J Am Coll Cardiol 2006; 47: 1741-53.

15. Blumel JE, Campodonico I. ¿Son los estrógenos transdérmicos cardioprotectores? Rev Méd Chile 2001; 129: 433-40.